Cyclacel Pharmaceuticals, Inc.
CYCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9,448 | $7,841 | $868 | $781,910 |
| - Cash | $4 | $4,275 | $3,450 | $3,137 |
| + Debt | $0 | $10 | $9 | $0 |
| Enterprise Value | $9,444 | $3,576 | -$2,573 | $778,773 |
| Revenue | $0 | $0 | $0 | -$35 |
| % Growth | – | – | 100% | – |
| Gross Profit | $0 | -$1 | $0 | -$39 |
| % Margin | 21% | – | – | 111.4% |
| EBITDA | -$1 | -$1,315 | -$5,035 | -$1,885 |
| % Margin | -1,208.6% | – | – | 5,385.7% |
| Net Income | -$1 | -$1,318 | -$81 | -$3,052 |
| % Margin | -1,219.8% | – | – | 8,720% |
| EPS Diluted | -1.31 | -0.84 | -6.25 | -0.35 |
| % Growth | -56% | 86.6% | -1,685.7% | – |
| Operating Cash Flow | $4,298 | -$1 | -$3 | -$1,356 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $4,298 | -$1 | -$3 | -$1,356 |